Faropenem

• UNSPSC Description:

  Faropenem is a potent and orally active beta-lactam antibiotic. Faropenem demonstrates broad-spectrum in vitro antimicrobial activity against many gram-positive and -negative aerobes and anaerobes. Faropenem is resistant to hydrolysis by nearly all beta-lactamases, including extended-spectrum beta-lactamases and AmpC beta-lactamases. Faropenem is developed as an oral proagent, faropenem medoxomil, for the research of respiratory tract infections[1][2].

• Target Antigen:

  Antibiotic; Bacterial

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/faropenem.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C(N12)=C([C@@H]3OCCC3)S[C@]2([H])[C@@H]([C@H](O)C)C1=O)O

• Molecular Weight:

  285.32

• References & Citations:

  [1]Kristen N Schurek, et al. Faropenem: review of a new oral penem. Expert Rev Anti Infect Ther. 2007 Apr;5(2):185-98.|[2]Stanley C Gill, et al. Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. Antimicrob Agents Chemother. 2010 May;54(5):1678-83.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  106560-14-9